Abstract
MDMA (±3,4-methylenedioxymethamphetamine)-assisted therapy (MDMA-AT) was shown in previous clinical trials to have promising efficacy and safety for alleviating treatment-resistant posttraumatic stress disorder (PTSD). However, due to low ethnoracial diversity, the question remains as to whether ethnoracial minority participants would benefit similarly. Thus, a mixed-methods case study was conducted on a participant of color from an open-label trial of MDMA-AT for PTSD to provide a culturally informed lens on symptom recovery with this treatment approach. An additional aim was to elucidate mechanisms of change underlying this treatment for the participant. A case profile was provided, documenting quantitative improvement in PTSD symptoms. This was followed by an interpretative phenomenological analysis (IPA) of effects and mechanisms of action for this participant, based on integration session transcripts. Results of IPA indicated recurrent themes related to psychological mechanisms of symptom change, reduced PTSD symptoms, and additional effects (positive and negative) beyond PTSD symptom reduction. These themes were discussed and recommendations for attuning to culturally relevant material during MDMA-AT were provided.
Keywords
Introduction
The unique pharmacodynamic effects of ±3,4-methylenedioxymethamphetamine (MDMA) in decreasing fear and anxiety and increasing trust and connectedness (Dolder et al., 2018; Sumnall et al., 2006) have prompted the investigation of MDMA-assisted therapy (MDMA-AT) as a “breakthrough treatment” for severe posttraumatic stress disorder (PTSD; Burge, 2017). MDMA-AT has been shown to support individuals in exploring and processing painful traumatic memories without being overwhelmed by arising distress (Feduccia & Mithoefer, 2018; Mithoefer, 2016). Recent studies based on pooled Phase 2 data support the efficacy of MDMA-AT for alleviating PTSD symptoms compared with placebo/control dose conditions at study termination (Mithoefer et al., 2019) and in an open-label sample at 12-month follow-up (Jerome et al., 2020). Furthermore, when comparing pooled Phase 2 data for MDMA-AT against historical data used for approval of paroxetine and sertraline, MDMA-AT showed larger effect sizes in reducing PTSD symptoms (Feduccia et al., 2019).
Knowledge regarding the psychological mechanisms of MDMA-AT remains sparse, however, in spite of numerous academic discussions of putative factors, such as openness to experiences (M. T. Wagner et al., 2017), enhanced emotion regulation (Johansen & Krebs, 2009; Sessa, 2017), trust and connectedness (Carhart-Harris et al., 2018; Jungaberle et al., 2018), discovery of insights about past trauma(s) (Grinspoon & Doblin, 2001; Hendricks, 2018), and self-compassion (McDaniel, 2017). One qualitative study conducted at 1-year follow-up examined perceived benefits of MDMA-AT beyond PTSD symptom reduction (Barone et al., 2019). Specifically, several participants reported gaining deeper self-understanding and self-compassion, which led to better management of their PTSD symptoms. Additional themes included improved familial and social relationships owing to enhanced empathy and social skills, increased engagement in new activities owing to motivation to “live life to the fullest” (Barone et al., 2019, p. 204), and reduced reliance on problematic substance use to cope with residual PTSD symptoms. Limitations of these themes include recall bias and/or other confounding factors post-MDMA-AT (e.g., life stressors or positive events that may influence or otherwise account for reported effects).
In addition, as in many clinical studies, the ethnoracial diversity of participants in MDMA-AT trials for PTSD has been and continues to be low. Only 12.4% of the pooled Phase 2 sample identified as individuals of color (Mithoefer et al., 2019). This is a serious limitation that is important to address, especially because individuals of color tend to be at increased risk of PTSD compared with non-Hispanic Whites (Alegría et al., 2013; Kisely et al., 2017; Roberts et al., 2011) due to systemic and interpersonal race-based stressors (e.g., racism, microaggressions; Carter, 2007; Sue et al., 2007). As a result, individuals of color may also face greater challenges in diagnosis and recovery from PTSD (Pérez Benítez et al., 2014), especially because these race-based stressors can occur even in health care settings (e.g., preferential treatment of White patients over patients of color; Shavers et al., 2012). There is currently little to no knowledge in the literature about whether MDMA-AT can be equally efficacious for treating PTSD in individuals of color.
In response to the limitations of extant research, we conducted a mixed-methods case study of a South Asian American participant who successfully completed a course of MDMA-AT for severe PTSD in an open-label trial. The first purpose of this study was to provide an idiosyncratic cultural lens on recovery from PTSD for this participant. The second purpose of this study was to detail more immediate and ecologically valid change processes and therapeutic mechanisms of action during MDMA-AT by analyzing session transcripts for this participant. In conducting this case study, we acknowledge limitations in the generalizability of the findings to participants from other marginalized ethnoracial groups and other MDMA-AT participants. Nonetheless, we hope that this case study can make a positive impact on the field by stimulating deeper considerations of cultural diversity and change processes as MDMA-AT research programs for PTSD advance.
Method
Open-Label Trial Design and Procedure
The present study involved a case study from an open-label trial (ClinicalTrials.gov identifier: NCT03282123) that was conducted across 12 sites in the United States. This trial served as a lead-in to ongoing Phase 3 randomized controlled trials of MDMA-AT for treatment of PTSD. Inclusion and exclusion criteria and procedural details for the trial are described in Wang et al. (2021). Eligible participants underwent three 1.5-hr preparatory psychotherapy sessions prior to their first MDMA dosing session. Participants received a total of three MDMA dosing sessions. Each MDMA dosing session lasted for most of the day (approximately 8 hr) and had an overnight stay that was supervised unobtrusively by a night attendant. Participants completed three 1.5-hr integration psychotherapy sessions after each MDMA dosing session, with the first integration session occurring the morning after each MDMA dosing session. Data collection for the open-label trial lasted from November 2017 to February 2019. The open-label trial was reviewed and approved by the Western Copernicus Institutional Review Board (IRB) and was designed and conducted in accordance with Good Clinical Practices.
Case Study Analytical Strategy
This mixed-methods case study adhered to the Case Report (CARE; Riley et al., 2017) and the Consolidated Criteria for Reporting Qualitative Research (COREQ; Tong et al., 2007) guidelines. First, a profile of the participant was assessed, including demographics, self-reported index trauma on the Life Events Checklist for Diagnostic and Statistical Manual of Mental Disorders (5th ed.; DSM-5; LEC-5; Weathers et al., 2013a), additional psychiatric diagnoses for which the participant met DSM-5 criteria at screening, and psychological and pharmacological treatment history. The participant’s vitals, adverse event(s), and drug test results throughout his participation were also assessed. In addition, changes in his PTSD (Clinician-Administered PTSD Scale for DSM-5 [CAPS-5]; Weathers et al., 2013b) and depressive symptoms (Beck Depression Inventory–Second Edition [BDI-II]; Beck et al., 1996), as well as suicidality (Columbia-Suicide Severity Rating Scale [C-SSRS]; Posner et al., 2008), from baseline to study termination, were assessed for further examination.
Next, transcripts of the participant’s nine integration sessions were qualitatively analyzed because integration sessions offer detailed information about insights that might have arisen during psychedelic experiences (Richards, 2017). Transcripts were first obtained in their raw form on the online Descript software (2019), edited for typos, and organized into dialogue format based on session recordings available on Descript. These transcripts were then entered into NVivo 12 (QSR International [Americas] Inc., 2018). All of the participant’s speech portions were coded for recurrent themes that detailed effects and potential mechanisms of change of MDMA-AT using interpretative phenomenological analysis (IPA; Smith et al., 2009). IPA emphasizes linkages among reported cognitions, emotions, and behaviors, which can be used to garner a variety of rich themes with even a single case. Transcripts were read and recursively coded in a data-driven manner. Saturated codes were then abstracted into higher-order themes. The coding team comprised of the lead author and the female study therapist (third author) from the participant’s male–female therapy team. Consensual agreement on reportable themes was reached, with an interrater reliability of .96. The coding team was restricted to these individuals due to the need for familiarity with MDMA-AT.
Results
Case Profile
Demographics, Trauma History, and Psychiatric Diagnoses
Kenneth (pseudonym) was an 18-year-old, first-generation, South Asian American, heterosexual, cisgender male college freshman. He was enrolled at a site in a university-affiliated academic medical center in the Northeast region of the United States. He was referred to the study by a friend, who was concerned about the distress he was expressing in relation to his experiences of trauma. Kenneth identified his index/worst trauma as sexual assault by a family friend at age 13 on four separate occasions over the course of 2 months. During the study, Kenneth reported that he has never disclosed his trauma to his parents, owing to cultural stigma, consistent with perceived stigma against mental illness and help-seeking among communities of color (Substance Abuse and Mental Health Services Administration [SAMHSA], 2012). He also endorsed multiple traumatic events in his late childhood to adolescence, including being the victim of violent, racially motivated bullying at school (e.g., being called racial slurs while being hit and punched by non-Hispanic White male classmates). Furthermore, on a camping trip, he witnessed a tree falling on his friends’ tent, killing two friends.
At baseline, Kenneth met DSM-5 criteria for PTSD; severe, recurrent major depressive disorder (MDD); and attention-deficit/hyperactivity disorder (ADHD), combined type. At the time of study enrollment, Kenneth reported no disability status and denied lifetime use of MDMA/ecstasy.
Treatment History
Kenneth had sought out supportive counseling for PTSD on several occasions in his adolescence, but did not engage consistently due to lack of perceived gains. He cited his parents’ stigmatizing beliefs about mental illness and mental health treatment as an additional barrier, even throughout his participation in the study. As a result, Kenneth had to keep his participation “a secret” from his parents. Three months prior to study enrollment, Kenneth was receiving twice-weekly individual cognitive-behavioral therapy (CBT) for PTSD and similarly reported lack of significant improvement in his PTSD symptoms. In terms of pharmacotherapy, Kenneth was prescribed Vyvanse (40 mg), which he took once daily orally for 2 weeks before study participation, before being switched over to Adderall (40 mg), to help with his ADHD symptoms during the academic semester. Kenneth was monitored throughout by the study physician in terms of limiting his ADHD medication to non-MDMA dosing periods (i.e., during integration phases).
Vitals, Adverse Event(s), and Drug Test Results
At screening, Kenneth exhibited normal electrocardiogram (ECG) and rhythm strip results, as well as normal clinical lab results. After enrollment, he voluntarily ingested the initial dose of MDMA for all three dosing sessions, which ranged from 80 to 120 mg. Kenneth also voluntarily ingested the supplemental dose of MDMA for the first two dosing sessions, which ranged from 40 to 60 mg. For the third dosing session, the supplemental dose was withheld because of elevated blood pressure following the initial dose. This adverse event was resolved by the end of the dosing session and did not require any medical intervention or further medical evaluation. Otherwise, Kenneth exhibited no other clinically significant elevations in his systolic and diastolic blood pressure, pulse, and body temperature throughout the study. The only other adverse event was mild headache at the end of the second MDMA dosing session, which was resolved with ibuprofen. Kenneth screened positive for cannabis use at informed consent, which he explained as recreational and self-medicative in nature. He agreed to discontinue cannabis use and consistently screened negative throughout the study.
MDMA-AT Outcomes
Kenneth was assigned to a therapist team consisting of a non-Hispanic White male psychiatrist and an African American female license-eligible marriage and family therapist. The psychiatrist withdrew for personal reasons after the third integration session following the second dosing and was replaced with a South Asian psychiatrist for the remainder of Kenneth’s study participation. This change in study therapists was discussed at length and in advance with Kenneth, who appeared amenable and open throughout the transition; Kenneth experienced clinically significant improvements in his PTSD symptoms (i.e., at least a 10-point reduction on the CAPS-5; Figure 1) and did not meet DSM-5 criteria for PTSD after the second dosing. Kenneth also experienced an improvement in his depressive symptoms (Figure 2). Kenneth reported positive ideation on the C-SSRS during preparatory visits, infrequently so (i.e., three instances) leading up to the second dosing, and did not endorse any positive ideation thereafter. Importantly, Kenneth did not report any treatment-emergent serious suicidal ideation or suicidal behavior.

Changes in Kenneth’s Clinician-Administered PTSD Scale for DSM-5 (CAPS-5) Score Across Sessions. Visit 3 Refers to the Baseline CAPS-5 Assessment Before the Third Preparatory Session. Visit 8 Occurred After the Second Integration Session After the First Dosing Session. Visit 13 Occurred After the Second Integration Session After the Second Dosing Session. Visit 19 Occurred After the Second Integration Session After the Third Dosing Session.

Change in Kenneth’s Beck Depression Inventory–Second Edition (BDI-II) Score Across Sessions. Baseline Assessment Occurred at Visit 4, the Preparatory Session Prior to the First Dosing Session, While Posttreatment Assessment Occurred at Study Termination (Visit 20).
Post-MDMA-AT Outcomes
After study termination, based on correspondence with his female study therapist, Kenneth reported continued “freedom from [his] PTSD.” He resumed individual talk therapy with a therapist outside of the study to continue “finding ways to move forward.” He was engaged in mental health activism, with a revitalized passion for helping others “find a way through their traumas.” Particularly, he reported being inspired and motivated to create and promote mental health initiatives for students of color on campus.
Master Themes
Three master themes meaningfully emerged: (a) psychological mechanisms of symptom change, (b) reduced PTSD symptoms, and (c) additional effects. Notably, there were meaningful connections among codes within and across subthemes, illustrating the complex and interwoven nature of effects and mechanisms of action of MDMA-AT for Kenneth.
Psychological Mechanisms of Symptom Change
Kenneth narrated several pathways of therapeutic change that meaningfully emerged as three subthemes: (a) trauma reprocessing, (b) cognitive change, and (c) emotional awareness and regulation (Figure 3). These descriptions provide a comprehensive response to the question, “How did MDMA-AT bring about symptom improvement for this participant?”

Subthemes (Trauma Reprocessing, Cognitive Change, and Emotional Awareness and Regulation) of the Master Theme, Psychological Mechanisms of Symptom Change.
Trauma Reprocessing
After the first dosing, Kenneth shared his experiences revisiting his index trauma without being overwhelmed: The challenging part was just diving into those memories. But I wasn’t crying. In fact, I was able to sometimes laugh at some things. I was able to really dive into my own mind. It’s like, “I’m gonna go for it.” And I just went in and did it, you know?
He also shared the experience of organizing his trauma memories neatly as folders in the filing cabinet that is his mind, and which are now voluntarily accessible: Now, I can remember if I want to, and I don’t have to remember if I don’t want to. Now, they’re all there, so that’s really nice. It almost felt like I was going through files yesterday. Like, “Hmm, where is the hidden file?” Now, I have access to the memories. It’s all there.
Kenneth also described metaphorical experiences of revisiting his sexual abuse rapidly as different “planets of experiences,” as a way to process them quickly and efficiently. He also described assuming a persona that allowed him to survey his “planets of experiences”: Each of my memories was its own planet, and I landed on each one. It was awesome really diving into and revisiting each of those memories. While all that was happening, I also remember becoming Galactus, a giant cosmic character in the Marvel Universe. So, I was just looking around, being him, and watching myself revisiting these memories.
Kenneth reported that in the first dosing session, he experienced the symbolic merging of his pretrauma, posttrauma, and ideal selves. In doing so, he removed the “mask” that he had put up to navigate life after his sexual trauma and reemerged as his authentic self. Kenneth utilized references to pop culture and his Hindu heritage in describing this integration of parts of himself: There was the innocent child, angsty teenager, and the adult God form. The innocent child is the one that existed before any of the abuse. The angsty teenager’s right after that, and the God is the final form. Now the innocent child’s happiness and pureness is mixing with that God-like form. I feel like now there’s no reason to be that angsty teenager anymore. The angsty teenager feels like a fallen soldier almost. You have done your service, go and rest. Let go of the pain. The pain the angsty teenager endured is still valid, he’s just not in the main picture anymore. It’s like when a Jedi dies. They don’t actually die, they just become a part of the Force. It’s also kind of like a Hinduism thing. In the Baghavad Gita, Krishna can be at times a baby. It can also be the chariot driver for Arjuna, and it can also have an all-powerful universal form too, you know? It’s kind of like all these things mixed together. Now, all of the parts of myself can work well together. And it’s really nice, because it’s easier to show up fully in all of my interactions and not have to hide or mask myself in different relationships.
Cognitive Change
After the first dosing, Kenneth expressed the insight that while his need for achievement and perfectionism was means of coping with the sexual trauma, these maladaptive patterns of thinking paradoxically served to maintain his difficulties in functioning. As a result of this newfound awareness, Kenneth reported being better able to challenge his thinking patterns in ways that he was not able to previously: Michael Phelps didn’t win a perfect 28 gold medals; he got a few silver and bronze medals on the way. That’s still an amazing achievement. In the past, I was striving to achieve, but I was never satisfied. Now, I’m satisfied. Instead of being negative or critical with myself, I’m more constructive with myself in a lot of ways.
He also accurately recognized that he was older now and less physically vulnerable, which made him less fearful about trauma-related cues and reminders: I’m grown now. There’s no real need to protect myself or be as fearful anymore. There’s no real danger anymore.
After the third dosing, Kenneth described a sense of self-efficacy in facing future stressors because (a) he believed that he was prepared to handle them, (b) he trusted that others (e.g., any therapist he might see in the future) would help him out, and (c) his PTSD symptoms were very much improved: I think there’s just a lot fewer things bothering me right now. I’m just ready to take things on. Everything just feels stable. Even with bad things happening in the future, I’ll be able to take care of myself. And if not, I’ll just ask others for help.
Emotional Awareness and Regulation
Kenneth reported experiencing emotions in their fullness during the first dosing session, which he discussed as different than his usual mode of “bottling things up.” He reported being able to release the anger—emotionally, verbally, and somatically—which he had attempted to suppress throughout his early teenage years after the sexual trauma. Kenneth also used motivational lyrics in rap music to bring forth positive emotions during the first overnight stay: This time I didn’t want to bottle it up. It’s not going back in my muscles. That’s not happening. Also, after the session, I put some Lil Uzi Vert on and I realized, Lil Uzi is so happy. There’s a song where he is like, “I can do what I want, I’m better now.” I was like, “Damn, that’s relatable.”
After the first dosing session, Kenneth reported successfully de-escalating arguments with his parents through affectionate behaviors (e.g., hugging them) or compromises, contrary to his behaviors pre-MDMA-AT. He attributed this change to an increased awareness of how negative emotions can worsen interpersonal conflicts: Every time they yell at me, I was just able to bring the situation back down. If I just calm myself down and give my mother a hug, she’ll relax and won’t freak out on me. It’s working pretty well.
Kenneth reported meditating regularly after the first dosing to practice calming down, to sustain feelings of calmness he experienced during that session. Meditation was also helpful in managing trauma-related anger and paranoia, to the extent that he was much less affected even in the presence of trauma triggers: I now like to meditate for brief periods because it helps me calm down. You know how some people describe being angry as holding on to something hot? That’s what it feels like to me when I’m meditating, like dropping a hot object. I also feel a lot less tense and paranoid.
After the second dosing, Kenneth also reported doing full-body stretches regularly, which he endorsed as a somatic strategy to release trauma-related muscle tension: I feel like I can breathe more, because I’m constantly like, stretching out. So much tension has been relieved from my body because of that.
After the first dosing, Kenneth described having a softer, more compassionate inner voice whenever he introspected about his current problems. He likened it to a “mature God voice,” one which was not so hard on himself, as opposed to his earlier “angsty teenager voice.” Furthermore, Kenneth was also able to experience compassion toward his perpetrator, as well as other sexual perpetrators. He described being able to see their pain and the reasons why they might have committed the crimes that they did: I don’t think anyone does anything bad because they’re inherently evil. I think they do it because they’re in some sort of pain, and this is what comes from that pain.
Reduced PTSD Symptoms
Kenneth further described various domains of PTSD symptom reduction that meaningfully emerged as four subthemes: (a) reduced intrusions, (b) reduced avoidance, (c) improved cognitions and mood, and (d) reduced vigilance and arousal (Figure 4). These descriptions provide a comprehensive response to the question, “What are the effects of MDMA-AT on PTSD symptoms for this participant?” These themes also correspond to Kenneth’s overall reduction in scores on the CAPS-5 (Figure 1).

Subthemes (Reduced Intrusions, Reduced Avoidance, Improved Cognitions and Mood, and Reduced Vigilance and Arousal) of the Master Theme, Reduced PTSD Symptoms.
Reduced Intrusions
Kenneth denied experiencing any flashbacks after the first two dosing sessions, which made it easier for him to focus on academic tasks. He expressed surprise at how his flashbacks were absent even just after the first dosing, even in the presence of trauma reminders. Furthermore, he described the function of flashbacks as his brain’s way of helping him fill in gaps in his index trauma memory, a function which was now unnecessary due to now having complete memory about his sexual abuse: A lot of times whenever I was doing anything, especially when I was working on things, sometimes I’d have flashbacks, and that would bother me a lot. I’d almost dissociate. I wouldn’t remember where I am, and then I’d have to recalibrate, because I’m distracted. Now I don’t have any flashbacks at all.
After the first two dosing sessions, Kenneth also denied experiencing trauma-related nightmares, which made it easier for him to “get on” with his day after waking in the morning: Now, when I have dreams at night, they’re normal. They’re not like the usual trauma nightmares. These days, I haven’t woken up in a cold sweat at all.
Reduced Avoidance
After the first dosing session, Kenneth reported mindfully approaching his trauma-related memories, which have decreased in frequency and intensity. He viewed them now as nonintrusive and was not distressed or overwhelmed by them: Now I just let those memories play through. I can easily deal with those experiences now. I don’t have to avoid them or distract myself.
Similarly, after the first dosing session, Kenneth reported mindfully approaching trauma-related reminders as well; in the past, he would engage in immediate avoidance to prevent the onset of distressing flashbacks: There was news on NPR about the Harvey Weinstein case, and I just let it play. I can now kind of deal with those experiences that remind me of the trauma, and not avoid them.
Improved Cognitions and Mood
After the first dosing session, through the use of the filing cabinet metaphor, Kenneth endorsed being able to remember everything about his sexual trauma. He believed that this was the reason why he no longer experienced flashbacks or other intrusive symptoms: Whenever I got the flashbacks, it felt like they were missing pieces that pop up, and were just another thing that I have to make sense of. It was one of those things that really bothered me. Like, how can I not remember something so big that happened to me as a kid? I think these pieces were just always buried in my brain, and my brain was constantly trying to remember the whole sequence of events. Now, I don’t need to keep searching, it’s just all there. Now, I remember everything.
After the first dosing session, Kenneth described being able to accept the sexual trauma as part of his life history, and being able to resolve his thoughts and feelings about his sexual trauma on a profound level. This was a stark contrast from his previous perseverative self-blame for not having been able to defend himself against the perpetrator. Due to improved PTSD symptoms, Kenneth also reported experiencing greater clarity, focus, and problem-solving ability, even with persisting inattention symptoms: I was going through the trauma in my head during the session. Just accepting it once again, affirming it, like, “Yes. It happened. But I’m alright now.” You know how when you have a problem and you deal with it and feel content afterwards because you handled the problem? It feels a lot like that, but on a deeper level. Things are a lot clearer, and I feel like I’ve just gotten so good at figuring out problems, that I don’t need to go to others for advice. It’s like archery, and I’m aiming for the bullseye, and I’m rapid firing, and I keep splitting the bows in half every time because it just keeps working.
Kenneth further reported that during the second dosing session, he was able to move beyond accepting to internally resolving his residual trauma-related feelings of paranoia, anger, and irritability: I was like, “Alright, I still have a few symptoms, let me go dive into those.” And I just went for it. There was a time when I sat up and I was repeating the symptoms that were bothering me. The paranoia, the irritability, the anger, I just kept naming them out loud over and over again until I started having that dialogue with these feelings, and then I was able to handle them. They don’t bother me now.
Finally, after the third dosing session, Kenneth articulated a deep sense of liberation from his trauma and wanted to metaphorically “charge forward into the unknown” that was his future and embrace it, instead of being afraid of it: It feels like I’m finally moving forward. It feels like the trauma has been taken care of. I’m figuring out what to do going forward. It’s really freeing. Now it’s time to charge forward into the unknown and see how things come out, and embrace what comes next.
After the first two dosing sessions, Kenneth also described experiencing sustainable feelings of happiness and optimism, increased motivation to accomplish things, and the belief that he can readily confront future challenges. These improvements were consistent with his pre–post session reduction in BDI-II scores (Figure 2): I just feel like my motors are running a lot quicker because there’s less gunk. Less sadness gunking up everything. It won’t even be a sunny and cheery day, and I would be like, “Let’s go do some work. Let’s get to it.” I’m smiling a lot more, and I feel a lot happier, in a sustainable way.
Reduced Vigilance and Arousal
After the first two dosing sessions, Kenneth described significantly reduced vigilance for signs of physical danger in his surroundings: In the past, I would have checked way more for safety. But last night after I closed my bedroom door and shut the blinds, I went right to sleep. It was interesting because I wasn’t worried, you know? I didn’t have to distract myself from thoughts about danger or anything.
After three dosing sessions, Kenneth described experiencing progressive somatic relaxation, being less “tensed up,” less physiologically aroused, and less jumpy, “on edge,” or irritable. For example, after the third dosing session, he said, It felt more physical than mental this time in terms of the experience. I was so relaxed. It just felt like I was sinking into the couch.
Kenneth also reported improved sleep quality, with significantly reduced waking during the night after the first two dosing sessions: It’s been really nice to get some solid sleep, to sleep soundly without waking from nightmares. With the MDMA, in my head, I’d just be like, “Take me.” And when I’m in bed, I just do the same thing. I just think to myself, “Take me,” and I fall asleep so easily.
Additional Effects
Kenneth narrated additional effects of MDMA-AT that meaningfully emerged as four subthemes: (a) reduced suicidality, (b) reduced illicit substance use, (c) pursuing priorities, and (d) negative effects (Figure 5). These descriptions provide a response to the question, “What are the effects of MDMA-AT beyond PTSD symptom reduction for this participant?”

Subthemes (Reduced Suicidality, Reduced Substance Use, Pursuing Priorities, and Negative Effects) of the Master Theme, Additional Effects.
Reduced Suicidality
During the first dosing session, Kenneth saw himself living life as a 60-year-old, which he interpreted as needing to abandon any distorted, suicidal ideation that may arise moving forward. He described the effects of MDMA as propelling him forward in time, so that he could envision life as his future self, with several strong reasons to continue living: The MDMA definitely helped me zoom forward, like seeing past the age 40. That was always the arbitrary number. It’s so much easier to believe you’ll live past that age if you can see past that age. It’s really hard to say you’re gonna die at 40 when you see yourself at 60. I just couldn’t hold onto that belief anymore. I’m done with thinking that way.
As a result of this insight, Kenneth experienced rapid reductions in the frequency and intensity of his suicidal thoughts. He described these thoughts as being much less egosyntonic and was able to easily and quickly control, dismiss, or ignore these thoughts with minimal distress. In addition, when his suicidal thoughts would occur, he reported being able to attend to activities that he would be engaging in, instead of being distracted by those thoughts. These changes were consistent with his reductions in suicidality on the C-SSRS: I had a suicidal thought just once. That was on Saturday. But I’d also like to point out that it was a lot different than before. It felt much more surface-level than actually, genuinely wanting to do it. And it was also much less intense. Before all this, it would feel like an 8 or a 9 out of 10, but now it’s at most 2 at the worst. I would say after a minute or two I was able to control and dismiss it pretty solidly.
Reduced Illicit Substance Use
Kenneth also expressed deep appreciation of how MDMA and other psychedelics purportedly catalyzed creativity in public figures whom he admired. At the same time, he was also cognizant that these substances should not be used recklessly and, after three dosing sessions, expressed no desire to engage in psychedelic use: I can now see why Steve Jobs did so much after taking psychedelics. In his biography or in the movie, they talk about how he wouldn’t have been who he was if he didn’t have those experiences that allowed him to think ahead of his time.
After the first two dosing sessions, Kenneth also expressed less desire or need for marijuana as a way to cope with his PTSD symptoms: I have much less need or want for weed now, since that was mostly to help with the PTSD. My friends brought me more weed for my birthday, and I was like, “I don’t want that, you know?” I cannot smoke while I’m in this study. I also just don’t want to smoke, you know? I don’t need to.
Pursuing Priorities
After the third dosing session, Kenneth reported feeling “hypermotivated” to accomplish multiple goals. He described this motivation as “laying dormant” prior to MDMA-AT and “reignited” due to the treatment. At the same time, although he was cognizant that he would need adequate sleep to have enough energy to pursue his goals, he reported being unsure as to how to achieve a “balance” between the two: I think one way to achieve something is if I work hard on it for a long time. If I get used to doing that, then that becomes my natural state. But I also know that for problem-solving and learning, sleep is very necessary. The problem is that there’s so much schoolwork. Add to that the important causes that I want to support that I sometimes forget about the fact that sleep is very necessary. I just have to figure out a way to find a balance.
One of Kenneth’s many priorities, besides mental health initiatives, was to create restorative justice initiatives targeting sexual misconduct on campus. To do so, he had to access and read complaints provided by the institution. Notably, this was another indication of nonavoidance of trauma reminders. He described feeling motivated to get implicated organizations on campus shut down, so that others would not be subjected to the sexual violations that these organizations seemed to perpetrate: If I pursue these cases and get these organizations shut down, or get an investigation into the system going and call people out and fix policy and get people removed, that’s a change that matters. Because that means that there would not be any people suffering in the future. And as long as I can do something about it, I’m going to do something about it.
Negative Effects
Kenneth experienced significant sleep deprivation after the third dosing, due to the start of the academic semester and Kenneth’s desire to accomplish multiple goals. Kenneth reported staying up most nights to complete schoolwork and work on his initiatives and, as a result, did not get sufficient sleep. He reported that his sleep debt, as well as his occasional overuse of his ADHD medication, had led to transient side effects such as mild visual blurring: I sleep very sporadically. During the week, there will be around two days where I just won’t sleep and then the weekend is when I catch up a lot on it, which is not healthy. And if I don’t sleep for a couple days, some things, like lines and colors, tend to blur, but it’s not very bad or noticeable. But like, how else does one get all of this work done?
Chest Discomfort
Post-third dosing, Kenneth would occasionally use more Adderall than prescribed, which he believed contributed to mild chest pain/discomfort, when coupled with his sleep debt. It was determined that this adverse event was not immediately related to MDMA-AT. He expressed the primary reason for his increased Adderall use as wanting to be able to complete all of his schoolwork so that he could pursue his various initiatives. He also expressed concern about having chest pains at his age and committed to comply with his prescribed dosage after study termination: I was on 30 mg of Adderall a while back, and it increased to 40 mg over the summer, but now I occasionally take 60 mg per day to help me get more work done. But whenever I do that, I would get light chest pain. It’s not something I’m used to. When I texted my brother, who’s in medical school, he said it’s probably the Adderall, and lack of sleep. I think so too.
Discussion
With the aid of a mixed-methods approach, the present case study was able to offer rich insights into the interwoven effects and mechanisms of action of MDMA-AT for a first-generation South Asian American participant in an open-label trial. Barriers to accessing MDMA-AT among communities of color may include a noninclusive research culture (Michaels et al., 2018), cultural misconceptions and aversion toward the use of psychedelic for healing (George et al., 2020; Neitzke-Spruill, 2020), as well as mistrust of medical research and settings (Suite et al., 2007; Williams & Labate, 2020). This case study provides a detailed report of a successful course of MDMA-AT for a participant of color. It is possible that Kenneth’s experiences might not be representative of those of other participants of color in the trial, as a function of his age, gender, race, ethnicity, and so on. Similarly, Kenneth’s experiences may also not generalize to other individuals who share his intersecting identities. Nonetheless, this case study provided a comprehensive examination of the complex routes through which PTSD symptom recovery was achieved for Kenneth.
Certain themes illustrated MDMA’s ability to dampen fear and anxiety related to traumatic memories so as to facilitate traumatic reprocessing (Mithoefer, 2016). After the first dosing, Kenneth was able to confront and develop healthier perceptions of his past traumas, viewing them as events in his past that had no objective influence on his present safety. Indeed, Kenneth was able to describe, without prior direction or suggestion, his trauma memories as neatly organized in the “filing cabinet” that is his mind, akin to metaphorical descriptions of how prolonged exposure (PE) for PTSD works in Foa et al.’s (2019) manual. Because MDMA allowed him to “dive deeper” into his traumas than he ever did before, he was also able to experience the integration of his pre-, peri-, and posttraumatic selves. This is similar to the goal of internal family systems (IFS) therapy, which assumes that there are internal parts within each individual that take on different roles (e.g., “exiles” who contain painful past experiences, “managers” who attempt to maintain everyday functioning, and “firefighters” who respond actively to imminent threats or crises; Schwartz et al., 2009). According to the IFS approach, optimal functioning is achieved when each internal part is recognized, validated, and valued, instead of being perceived as problematic or needing to be repressed (Green, 2008). This allows them to function as a cohesive whole. Therefore, through this integration of his various selves, Kenneth recognized the value of his “angsty teenager” in helping him cope with the sexual trauma and was able to allow each of his internal parts to coexist without any part dominating the way he behaved or perceived the world. In addition, Kenneth was able to identify and challenge cognitive distortions that would often leave him feeling upset or “stuck” and felt sufficiently resourced after the third dosing to navigate future challenges without worrying excessively about their outcomes.
The remaining mechanistic themes also overlapped in several ways with themes from Barone et al.’s (2019) study with predominantly non-Hispanic White participants, perhaps indicative of cross-cultural mechanisms. For example, Kenneth reported increased awareness of negative and positive emotions, choosing to acknowledge their presence instead of minimizing them or “bottling them up.” In addition, Kenneth increased his use of healthy emotion regulation strategies (e.g., responding with affection, meditation, stretching) during times of stress or conflict. Furthermore, Kenneth developed a softer, more compassionate inner voice to help defuse from situations that would otherwise frustrate him and was even able to develop compassion toward his perpetrator and his parents. These changes preceded his reductions in PTSD symptoms. Kenneth’s reported themes of PTSD symptom recovery also reflected these synergistic processes of internal change.
There were additional similarities between other themes in this case study and those from Barone et al.’s (2019) study, such as Kenneth’s increased motivation to engage in various new activities that aligned with his academic and social justice aspirations. This change in priorities is akin to posttraumatic growth, which has been demonstrated among individuals in previous MDMA-AT trials (Gorman et al., 2020). A distinction, however, was that while his social justice initiatives allowed him to cultivate his interest in posttraumatic advocacy, Kenneth also experienced detrimental effects that appeared interrelated, such as occasional overuse of his ADHD medication to complete schoolwork, resultant insufficient sleep, and transient chest discomfort. In other words, the present case study offered a more balanced view of both positive (i.e., symptom reduction, increased motivation) and negative, albeit transient, effects (i.e., sleep changes, use of medication other than prescribed, chest discomfort) of MDMA-AT. In addition, a distinct benefit was Kenneth’s reduced suicidality, owing to his experience of seeing himself as a 60-year-old during the first dosing session. This was consistent with Kenneth’s reduced endorsement of suicidal ideation on the C-SSRS throughout the study.
Notably, Kenneth’s experience during the first dosing session offered a rich lens into his cultural and religious heritage. Specifically, Kenneth likened the merging of his selves to Krishna, a Hindu deity characterized by his multiple, integrated personas (Mahony, 1987). This integration of his selves, akin to Krishna’s personas, was pivotal because it empowered Kenneth to “move forward” from his traumas while allowing him to honor the pain that his younger self had endured. At the same time, there were pop culture references in his descriptions emblematic of his identity as a consumer of American contemporary media as well (e.g., likening the merging of his selves to when a Jedi merges with the Force). While there is documented evidence of transcultural, heightened spirituality induced by psychedelic experiences (Lerner & Lyvers, 2006), the emergence of idiosyncratic cultural iconography within psychedelic experiences is not a unique phenomenon. For example, Ching (2020) similarly described visions of culturally significant icons from his Southeast Asian heritage (e.g., native flora and fauna, Chinese calligraphy) catalyzing important insights during his MDMA-AT experience in a clinical trial (ClinicalTrials.gov identifier: NCT01404754). In addition, in A. C. Wagneret al.’s (2019) case example of a religiously devout Christian couple (one partner with PTSD) who underwent MDMA-assisted cognitive-behavioral conjoint therapy (CBCT), there were significant visions of Jesus providing comforting gestures reported during the dosing sessions. All of these observations perhaps illustrate the importance of acknowledging how one’s cultural or religious heritage can enter the psychedelic experience to induce meaning-making processes, which may in turn promote recovery from pathological patterns of functioning. As such, when culturally and/or religiously salient psychedelic experiences emerge, it may be pertinent for therapists to respond in sensitive and attuned ways (e.g., expressing curiosity and supporting deeper exploration of emerging experiences while suspending stereotyped interpretations), so as to facilitate development of lasting insights. For example, Kenneth’s therapists were attuned to the role cultural dynamics (e.g., religious heritage) played in his symptom presentation. During the second dosing session, more tracks containing or sampling Hindu mantras were incorporated into the music playlist to support Kenneth in processing his various childhood traumatic experiences. Kenneth’s therapists were also attuned to his preferred means of verbal expression and trauma processing (i.e., rapping), encouraging him to narrate his thoughts and feelings via rapping during the first dosing session. Interested readers are advised to peruse additional recommendations described in Williams et al. (2020), which were followed in Kenneth’s care.
Other parallels exist between Kenneth’s MDMA-AT experience and core mechanisms of change for established psychological treatments for PTSD. For example, Brown et al. (2019) detailed how reduction of negative trauma-related cognitions can then allow for more adaptive associations between the trauma and one’s life, future, and the world during PE for PTSD. These mechanistic changes may also occur cross-culturally, as inferred from similarities in response to PE for PTSD across ethnoracial groups (e.g., Kline et al., 2020). In fact, improvements in dysfunctional trauma-related cognitions were shown to be a pervasive mechanism of change across diverse psychological interventions for adults and children who have experienced traumatic stress (Kangaslampi & Peltonen, 2019). In addition, reductions in trauma-related cognitive appraisals have been shown to precede sudden gains in PTSD symptom improvement in routine care for individuals with PTSD (Wiedemann et al., 2020). These findings reflect what was observed for Kenneth, in that his alterations in dysfunctional, trauma-related cognitions (e.g., self-blame, perfectionism) after the first dosing session preceded the clinically significant drop in his CAPS-5 score after the second dosing session. Indeed, Kenneth no longer met DSM-5 diagnostic criteria for PTSD after the second dosing session. Furthermore, other research has supported how reductions in experiential avoidance preceded symptom improvement in CBT for various behavioral disorders, including PTSD (Eustis et al., 2019; Hayes et al., 1996). This is similar to how Kenneth was able to “survey” his past traumatic experiences without avoidance of emerging memories and feelings during the first dosing session, continue to approach trauma reminders after the first dosing, and experience clinically significant improvement in PTSD symptoms after the second dosing session. The aforementioned observations lend support to why MDMA-AT might at least be comparable with evidence-based psychotherapies for PTSD (Amoroso & Workman, 2016), as there may be similar mechanisms of change involved.
At the same time, there are procedural distinctions between MDMA-AT and CBT for PTSD. First, therapists in the open-label trial underwent an extensive MDMA-AT training program, which included an experiential component of a single dosing session. This depth of training is perhaps distinct from CBT training programs for PTSD, in which therapists’ prior experience in receiving, for example, PE, is not required for administering the treatment (Foa et al., 2019). This level of immersion in MDMA-AT training might have also allowed for the therapists to better understand the spectrum of experiences that might emerge for participants during dosing sessions, which might in turn strengthen the relational bond with participants, crucial for retaining participants of color, who might be at higher risk of dropping out (Lester et al., 2010). Nonetheless, it may be impossible given the present data to attribute certain change processes (e.g., cognitive change) as specific to MDMA-AT, given overlap with CBT for PTSD. As such, future research should attempt to dismantle mechanistic processes of MDMA-AT to better understand its distinctions from and commonalities with CBT approaches for treating PTSD.
It is hoped that the themes gleaned from this case study would inform future research in various ways. For example, measures can be implemented or developed to better assess the discussed mechanisms of change during MDMA-AT. A larger-scale analysis of transcripts from other participants can also be conducted to converge on commonly experienced effects. It would also be interesting to examine the possible impact of therapists’ diverse cultural backgrounds and professional training (e.g., pastoral counseling) on the nature of participants’ experiences (e.g., spiritual and religious themes) during MDMA-AT. More importantly, this case study offered a culturally sensitive lens into an ethnoracial minority participant’s recovery from PTSD with MDMA-AT and hopefully would serve to inform readers and potential participants of color about the utility of this treatment for addressing their own PTSD-related problems. In fact, although the sexual trauma was the focus of his MDMA-AT experience and there was no explicit linking of his perceived changes and insights to his past racial traumas based on the transcripts, in a recent media interview, Kenneth did express gaining a long-lasting respite from suicidality attributable to his past racial trauma as well (Favaro et al., 2021). Thus, it appeared that Kenneth’s experience with MDMA-AT for treatment-resistant PTSD was overall a positive and beneficial one, despite multiple past and ongoing cultural and familial barriers to psychotherapy. However, even at the end of the study, Kenneth still had not disclosed both his sexual trauma and his participation in the study to his family. He clarified that this was because his PTSD symptoms have remitted and because he was realistically cognizant of his limited ability to change his parents’ stigmatizing attitudes toward mental illness and mental health treatment. On the contrary, for many ethnoracial minority participants, these barriers to symptom disclosure or family support in treatment might mean the difference between continuing in treatment or dropping out, or even refusing to begin treatment altogether (Gary, 2005). Therefore, the need for culturally responsive strategies to circumvent these barriers in recruitment (and perhaps retention) becomes ever more urgent (see Williams et al., 2020, for recommendations).
Footnotes
Acknowledgements
The authors would like to thank the case study participant for consenting to the use of his deidentified experience in this research. The authors would also like to thank Stephanie Milan, PhD; Amy Gorin, PhD; Kimberli Treadwell, PhD; and Matthew D. Skinta, PhD, for their comments on the initial version of the manuscript. In addition, the authors would like to acknowledge the collective wisdom from the inaugural MAPS Therapists of Color training program for MDMA-AT for inspiring this process. Finally, the authors would like to acknowledge the efforts of Jamilah R. George, MDiv; Destiny M. B. Printz, MS; and Jennie Purdon, BA, in helping this research come to fruition.
Author Contributions
T.H.W.C. conceptualized this research, conducted the literature search, analyzed the data, and drafted the initial version of the manuscript. S.J.R. shared some data analysis duties. All authors contributed to the critical review and final version of the manuscript.
Declaration of Conflicting Interests
The author(s) declared the following potential conflicts of interest with respect to the research, authorship, and/or publication of this article: A.E. and J.B.W. received salary support for full-time employment with MAPS Public Benefit Corporation (MAPS PBC). B.Y.-K. and R.D. received salary support for full-time employment with Multidisciplinary Association for Psychedelic Studies (MAPS).
Funding
The author(s) disclosed receipt of the following financial support for the research, authorship, and/or publication of this article: This research was funded by a research grant from the Source Research Foundation and by the University of Connecticut Graduate School Dissertation Fellowship. The clinical trial was sponsored by the Multidisciplinary Association for Psychedelic Studies (MAPS), a 501(c)(3) nonprofit organization. MAPS provided the MDMA and fully funded this study from private donations. MAPS Public Benefit Corporation (MAPS PBC), wholly owned by MAPS, was the trial organizer.
